Financial Performance
5Y price score: 80
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 165.1%
US$ Per
Share
By default your notes are visible only to you.
173.3
52-week range
276.4
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.8 %
Dividend Yield TTM
1.9 %
Market cap $
$ 658,240
Price / Earnings TTM
31.7
Price / Book TTM
7.8
PEG TTM
(36.2)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
56 %
70.2 %
165.1 %
Free cash flow per share growth
35.5 %
7.3 %
44.2 %
Earnings per share growth
(0.9) %
100.2 %
101.3 %
Founded: 1,886
Employees: 138,100
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 15, 2026)
1) Strategy & Leadership
- Joaquin Duato, CEO, emphasized 2026 as a year of accelerated growth, reporting strong Q2 results and raised guidance.
- The company has 28 products generating over $1 billion in annual sales, showcasing a robust portfolio and pipeline.
- Johnson & Johnson aims to be the number one oncology company by 2030, with projected sales exceeding $50 billion.
2) Financial & Segment Results
- Q2 2026 worldwide sales reached $25.3 billion, a 5.6% increase YoY, with operational growth of 6.8% in Innovative Medicine.
- Net earnings were $5.5 billion, with diluted EPS of $2.27. Adjusted EPS increased to $2.90, up 4.7% YoY.
- Key growth drivers included:
- Oncology: DARZALEX grew 17.6%, CARVYKTI 47.7%, and TECVAYLI 56.1%.
- Immunology: TREMFYA surged 71%, while STELARA declined 55.7% due to biosimilar competition.
- MedTech: Sales of $8.9 billion grew 3.6%, with notable performance in cardiovascular and surgery segments.
3) Problems / Headwinds
- STELARA's decline impacted overall growth, contributing to a 460 basis point headwind.
- Abiomed's growth slowed due to increased physician selectivity and a recent neutral clinical trial affecting procedure volumes.
- Competitive pressures in MedTech, particularly in electrophysiology, contributed to lower-than-expected growth.
4) Operational or Product Plans
- New product launches, including ICOTYDE and INLEXZO, are expected to drive future growth, with ICOTYDE showing strong early uptake.
- The company plans to acquire Firefly Bio to enhance its oncology pipeline.
- Upcoming catalysts include FDA approvals for several products and continued expansion in the robotics segment with OTTAVA and MONARCH.
5) Guidance & Outlook / Investor Angle
- Full-year operational sales growth guidance increased to 6.5%-7.1%, with a projected midpoint of $100.6 billion.
- Adjusted operational EPS guidance raised to $11.50-$11.65, reflecting a 7.3% YoY growth.
- The company remains committed to returning capital to shareholders primarily through dividends, while maintaining a strong cash position of approximately $21 billion.
Bottom line: Johnson & Johnson's strong Q2 performance and raised guidance reflect a solid growth trajectory, driven by a diverse portfolio and innovative product launches, positioning the company favorably for long-term shareholder value.
Annual Reports, Presentations And IR Contacts
Go to the websiteJohnson & Johnson — Financial Overview, Stock Price, Market Cap
Johnson & Johnson is a company. Founded in 1886. As of August 26, 2026, the company's market capitalization is $658239653346 with a current stock price of $273.14.